Form 4: Axogen Director Amy Wendell Receives Annual Equity Grant of Restricted Stock Units

Axogen, Inc. Director Amy McBride Wendell has been granted 14,150 restricted stock units as part of her annual equity compensation for board service, vesting in June 2026.

Summary

• Amy McBride Wendell, a Director of Axogen, Inc. (AXGN), was granted 14,150 Restricted Stock Units (RSUs) on June 19, 2025.
• Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.
• The grant is an annual equity compensation for her service on the Axogen, Inc. Board of Directors.
• The number of shares granted is based on a valuation of $150,000 as of the grant date.
• The RSUs are scheduled to vest on June 19, 2026, which is the one-year anniversary of the grant date.
• Following this transaction, Amy McBride Wendell beneficially owns 14,150 Restricted Stock Units directly.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for corporate governance as it aligns interests, but it is not a significant market-moving event.

Positives

• The equity grant aligns the director's financial interests with those of the shareholders, promoting long-term value creation.
• It represents a standard practice for compensating board members, indicating stable corporate governance practices.

Future Outlook

The granted Restricted Stock Units are scheduled to vest on June 19, 2026, contingent upon continued service as a director.

Industry Context

The granting of equity compensation, such as Restricted Stock Units, to non-employee directors is a common and widely accepted practice across various industries, including the medical technology sector where Axogen operates. This method is used to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, typically in the form of stock options or restricted stock units, is a standard practice across publicly traded companies, including those in the medical device and biotechnology sectors.
• The valuation of the grant ($150,000) for annual director service is within the typical range observed for non-executive directors at companies of similar market capitalization and industry, though specific benchmarks would require detailed peer group analysis.
• The one-year vesting period is a common structure for annual director equity grants, ensuring continued commitment over the short to medium term.

Corporate Governance

Related Party Transactions

• The grant of 14,150 Restricted Stock Units to Amy McBride Wendell, a Director of Axogen, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder interests, potentially leading to better long-term decision-making.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest on June 19, 2026, subject to the terms of the grant.

Key Dates

Keywords

Axogen, AXGN, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, Corporate Governance